These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9175038)

  • 1. The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists.
    Kooistra MP; Marx JJ
    Nephrol Dial Transplant; 1997 May; 12(5):879-83. PubMed ID: 9175038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron status and iron supplementation in peritoneal dialysis patients.
    Vychytil A; Haag-Weber M
    Kidney Int Suppl; 1999 Mar; 69():S71-8. PubMed ID: 10084290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron monitoring and supplementation: how do we achieve the best results?
    Schaefer RM; Schaefer L
    Nephrol Dial Transplant; 1998; 13 Suppl 2():9-12. PubMed ID: 9566484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to get the best out of r-HuEPO.
    Hörl WH
    Nephrol Dial Transplant; 1995; 10 Suppl 2():92-5. PubMed ID: 7644113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron metabolism and iron substitution during erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Clin Investig; 1994; 72(6 Suppl):S11-5. PubMed ID: 7950165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin and iron.
    Sunder-Plassmann G; Hörl WH
    Clin Nephrol; 1997 Mar; 47(3):141-57. PubMed ID: 9105761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
    Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
    Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
    Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
    Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
    Daschner M; Mehls O; Schaefer F
    Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin.
    Kooistra MP; van Es A; Struyvenberg A; Marx JJ
    Br J Haematol; 1991 Dec; 79(4):634-9. PubMed ID: 1772785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
    Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
    Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.